A Phase 2 interventional study of serogroup B meningococcal vaccine and serogroup B meningococcal vaccine in Meningococcal Disease, sponsored by Novartis Vaccines. Completed at 8 sites in United States. Open to participants aged 11 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-12-01.
Sponsored by Novartis Vaccines · Phase 2, Interventional, and Prevention
The purpose of this study is to evaluate the safety and immunogenicity of two serogroup B meningococcal vaccines in comparison to placebo administered to healthy adolescents ages 11 to 18 years.
219 studies on the registry are indexed under Meningococcal Infections; 6 are open to participants now.
This study's enrollment of 203 is below the median of 450 across 190 interventional studies indexed under Meningococcal Infections.
Browse Meningococcal Infections studies →Novartis Vaccines is the lead sponsor of 161 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Biological: serogroup B meningococcal vaccine
Biological: serogroup B meningococcal vaccine
Biological: serogroup B meningococcal vaccine
0.5mL doses in pre-filled syringes. All subjects will receive the study vaccine following a 0,2,6 vaccination schedule.
0.5mL doses in pre-filled syringes. All subjects will receive the study vaccine following a 0,2,6 vaccination schedule.
0.5mL doses in pre-filled syringes. All subjects will receive the placebo following a 0,2,6 vaccination schedule.
Safety, tolerability and immunogenicity as measured by serum bactericidal activity of the two vaccines in healthy adolescents
Time frame: 1 month after completion of immunization schedule
Safety, tolerability and immunogenicity as measured by serum bactericidal activity of the two vaccines in healthy adolescents
Time frame: 6 months after completion of immunization schedule
This study is completed, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Novartis Vaccines